The Pharma Data

JUNE 15, 2025

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. Serious adverse events were somewhat lower in Dupixent (2%) than in omalizumab (4%).

Treatment

The Pharma Data

JUNE 23, 2025

Safety Profile and Tolerability: No Surprises, GI Events Mostly Mild In terms of safety, the Phase 2 study did not identify any new safety signals. The most common adverse events (AEs) reported were GI-related , including nausea and vomiting, and were generally mild to moderate in severity.

Trials

Pharma Manufacturing

JUNE 17, 2025

Magazine ENEWS SUBSCRIBE WEBINARS PODCASTS EBOOKS ABOUT US Edit submissions Media kit Innovation Awards Articles Flow state: The evolving shape of continuous manufacturing June 17, 2025 While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.

RNA

Broad Institute

NOVEMBER 25, 2024

As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner. We will keep you in the loop on upcoming events and research highlights.

Clinical Trials

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., of patients receiving sibeprenlimab compared to 84.5%

Trials

The Pharma Data

JUNE 20, 2025

For some, however, disease management becomes even more precarious due to impaired hypoglycemia awareness and a heightened risk of severe hypoglycemic events (SHEs). Zimislecel was generally well tolerated, with most adverse events categorized as mild to moderate. No serious adverse events were attributed to the treatment itself.

Therapies

BioPharma Drive: Drug Pricing

AUGUST 13, 2025

Vertex Pharmaceuticals and Vera Therapeutics are also developing BAFF- and APRIL-targeting drugs, but are aiming first at a kidney condition called IgA nephropathy. You can unsubscribe at anytime. And just this week, Novartis said a monoclonal antibody that blocks the BAFF receptor succeeded in two Phase 3 studies it ran in Sjögren’s.

Licensing

SugarCone Biotech

JUNE 27, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Therapies

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. 4 patients (33%) had grade 4 adverse events. Importantly, effective combinatorial approaches that include these targets are emerging.

Therapies

BioPharma Drive: Drug Pricing

JULY 14, 2025

The most common adverse events reported were insomnia as well as the sudden urge to urinate. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Drugs

Drug Target Review

AUGUST 8, 2025

By evaluating cytokine profiles in vitro , developers can flag molecules with higher risk profiles and reduce the chance of triggering adverse events in the clinic. Dr Petra Dieterich Dr Petra has 30 years’ experience of drug development in the pharmaceutical industry with a focus on supporting CMC activities.

Engineering

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. The extensive data requirements for regulatory submissions further complicate the process.

Drug Development

The Pharma Data

AUGUST 3, 2025

The frequency of device-related complications remained low, and the majority of adverse events were either mild or moderate in severity. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. Importantly, the refillable nature of the implant proved durable across the extended treatment period. Source Link

Treatment

Drug Patent Watch

MARCH 27, 2025

Revolutionizing Generic Drug Development: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. AI-powered tools can accelerate development times, reduce costs, and improve product quality.

Drug Development

The Pharma Data

JULY 2, 2025

Safety analysis from the HERIZON-BTC-01 study revealed that the most common adverse reactions included: Diarrhea (46%) Infusion-related reactions (33.3%) Abdominal pain (26.4%) Anemia (25.3%) Fatigue (24.1%) Serious adverse events were reported in 16.1% Ziihera is being jointly developed by Jazz Pharmaceuticals and BeOne Medicines Ltd.

Therapies

Elrig

MARCH 25, 2025

Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this years event focussed on drugging the undruggable.

RNA

The Pharma Data

JUNE 25, 2025

Additionally, the tablet form supports flexible dosing and simplifies dose reductions, which may be required due to drug interactions or adverse events, as guided by the product’s label. These sustainability considerations align with growing global demand for environmentally responsible pharmaceutical manufacturing and distribution.

Packaging

Drug Target Review

JULY 14, 2025

The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues.

Drugs

Alta Sciences

NOVEMBER 4, 2024

Case Study: How to Ensure Safety While Manufacturing Highly Potent APIs aasimakopoulos Mon, 11/04/2024 - 17:37 Highly potent active pharmaceutical ingredients (API) require careful attention to safety and handling during formulation and manufacturing.

Engineering

The Pharma Data

JUNE 9, 2025

Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran).

Treatment

Drug Target Review

MARCH 17, 2025

Advancing drug candidates across key therapeutic areas Dr John Donello brings over 25 years of experience in pharmaceutical drug discovery, development and collaborations. Event-driven pharmacology Donello highlights the growing recognition of synaptic plasticity’s crucial role in the biology of depression.

Treatment

Alta Sciences

JULY 23, 2025

The event proved to be a dynamic reflection of the current flow cytometry landscape. Following the completion of a Doctor of Philosophy in Pharmaceutical Sciences from the Université de Montréal, and several years in the CRO industry, he has developed extensive expertise in flow cytometry technologies.

International

Drug Target Review

JUNE 5, 2025

5,6 The 2023 approval of two engineered stem cell-based therapies marked a significant advancement, though these options require careful consideration of potential adverse events and long-term safety, 7 and access will remain a challenge for the foreseeable future. There was a predicted 21.5 JAMA Netw Open. 2023 Nov 1;6(11):e2344546.

Disease

Drug Patent Watch

DECEMBER 17, 2024

Let’s dive into the world of pharmaceutical outsourcing and explore why adaptability is the key to success. The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Responding to Market Demands The pharmaceutical market is notoriously unpredictable.

Pharmaceuticals

DrugBank

JULY 14, 2025

For instance, polymorphisms in CYP2C19 can cause poor or extensive metabolism of certain drugs, like clopidogrel , leading to either ineffective therapy or a heightened risk of adverse events.

Clinical Development

ACTO

AUGUST 11, 2025

About Global Data Support (GDS) Global Data Support (GDS) helps biopharma and pharmaceutical companies find patients, profile experts, and map treatment landscapes—especially in rare diseases and oncology.

Disease

BioPharma Drive: Drug Pricing

JUNE 11, 2025

© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. View our other publications | Privacy policy | Terms of use | Take down policy. TechTarget, Inc.s registered office is 275 Grove St. Newton, MA 02466.

FDA

thought leadership

FEBRUARY 10, 2025

For pharmaceutical companies, this shift presents both challenges and opportunities. In today's digital age, social media has transformed how businesses communicate with their audiences. Social media can significantly enhance brand visibility and patient engagement and have an impact on the overall healthcare sector.

Pharmaceutical Companies

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Drug Development

New Drug Approvals

JULY 2, 2025

1] It was discovered by Chugai Pharmaceutical Co. 3] Safety and dosing trials showed that the incidence of adverse events in orforglipron-treated participants was 62–89%, mostly from gastrointestinal discomfort (44–70% with orforglipron, 18% with placebo) having mild to moderate severity. [6] then was licensed to Lilly in 2018. [1]

Small Molecule

Codon

JANUARY 5, 2025

In an amusing turn of events, the six-man committee of Harvard's best life science researchers decided that they needed an MIT man to get the job done — the lecturer, Larry Oncley. With the construction of the pilot plant, Cohn built a scientific environment at Harvard that mimicked commercial pharmaceutical factories in one fell swoop.

Laboratories

Pharma Manufacturing

JULY 21, 2025

“If the pharmaceutical sector experiences a slowdown phase, pipeline figures might shrink, driving a slowdown in revenue growth for outsourcing firms,” the credit ratings agency said. For more than 20 years, Greg has covered the healthcare, life sciences, and medical device industries for several trade publications.

Therapies

LifeSciVC

JUNE 12, 2025

We intended to learn from nature (genetics) and use pharmaceuticals properties to drive patient benefit. We aimed to achieve this by modifying and modulating proteins by precisely changing a single alphabet on RNA with the use of an oligonucleotide (think short stretches of chemically modified RNA or DNA).

RNA

New Drug Approvals

APRIL 11, 2025

1] [2] Adverse effects The US Food and Drug Administration prescription label for fitusiran contains a boxed warning for thrombotic events (blood clotting) and gallbladder disease (with some recipients requiring gallbladder removal). [2] Fitusiran 1711.0g/mol, 1] It is an antithrombin-directed small interfering ribonucleic acid. [1]

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 16, 2025

Aside from the Duchenne medicines it sells, Sarepta intends to focus resources moving forward on a group of RNA-based medicines it’s developing with Arrowhead Pharmaceuticals. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Therapies

BioPharma Drive: Drug Pricing

JULY 10, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. You can unsubscribe at anytime. TechTarget, Inc.s

Vaccine

BioPharma Drive: Drug Pricing

JULY 10, 2025

But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations. You can unsubscribe at anytime.

Drugs